| Bioactivity | LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC50 of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC50 of 8.79 μM[1]. |
| Invitro | LSD1/ER-IN-1 (compound 11g) (0-30 μM, 24 h) induces apoptosis in MCF-7 cells in a dose-dependent manner[1]. |
| Name | LSD1/ER-IN-1 |
| Formula | C23H18FNO6S |
| Molar Mass | 455.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. He M, et al. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer. Eur J Med Chem. 2020 Jun 1;195:112281. |